Study ID: SH ADAM 12
Description:

Urinary expression of ADAM12 as a tumor marker for breast cancer treatment response

Location:
Fargo Region
Principal Investigator:
Neville Alberto MD
Disease:
Breast - Invasive
Stage:
N/A

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list